Study S001321

The Effect of Semaglutide (Ozempic) on Bone Turnover in Patients With Increased Fracture Risk: a Randomized Placebo-controlled Clinical Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT04702516
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1; PHASE2
Masking: QUADRUPLE
Status: UNKNOWN
Enrollment: 64
Start: 2021-03-24
Primary completion: 2022-08-31
Lead sponsor: Morten Frost
Conditions: Osteopenia
Interventions: DRUG:Ozempic; DRUG:Placebo
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2020-000616-29; OTHER_GRANT:0052699; OTHER_GRANT:18/51856; OTHER_GRANT:A35844

Registered primary outcomes

Procollagen type 1 N-terminal propeptide (P1NP) [Baseline and 52 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0011399	Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial. Hansen MS, EClinicalMedicine	2024	Randomized trial	PMID 38737002 DOI	cites ClinicalTrials.gov:NCT04702516; registry reference DERIVED:38737002